Researchers at the Department of Translational Medicine, University of Ferrara, Italy, and colleagues in the ERN-EYE Network, have published paper on the first study to… Read More »Real-world impacts of an observational study on X-linked retinitis pigmentosa (XLRP) patients’ experience, supported by the ERN-EYE Network.
RhyGaze AG, based in Basel, Switzerland and Philadelphia, Pa., USA, have announced a Series A financing of USD $86 million for their company, aimed to… Read More »RhyGaze AG (Switzerland) receives $86M funding for optogenetic vision restoration, a spin-out of the Institute of Molecular and Clinical Ophthalmology, Basel.
Dear EURETINA Members, A very warm welcome to the January 6th, 2025 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »January 6th, 2025 “EURETINA-Brief”© Issue No. 307
Researchers at the Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand, have reported a D126G missense mutation in the RS1 gene, causing… Read More »The D126G mutation in RS1 gene, causing X-linked juvenile retinoschisis (XLRS), shows the highest prevalence of the disorder in a Thailand study.
Researchers at the Department of Ophthalmology, Seoul National University College of Medicine, South Korea, have conducted a study to evaluate the national incidence of rare… Read More »A nationwide study on the incidence of rare retinal diseases in South Korea reports 1.1M clinical records.
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) have announced that aflibercept (injection 8 mg) met the primary endpoint for the treatment of patients with macular oedema following… Read More »Aflibercept injection (8 mg, Eylea HD) for the treatment of macular oedema following retinal vein occlusion (RVO) meets primary endpoint.
Dear EURETINA Members, A very warm welcome to the December 21st, 2024 edition of EURETINA’s web-based digital periodical, “EURETINA Brief”. EURETINA are delighted to continue… Read More »December 21st, 2024 “EURETINA-Brief”© Issue No. 306
Researchers at the Gavin Herbert Eye Institute, Department of Ophthalmology, University of California, Irvine, has reported an experimental treatment using a CRISPR/Cas9 adenine base editing… Read More »Autosomal-recessive retinitis pigmentosa (arRP) – a mutation (E150K) of rhodopsin may provide a CRISPR treatment with functional and structural rescue.
Researchers at the Casey Eye Institute, Oregon Health & Science University (OHSU), Portland, USA, have provided formal results of a Phase 1/2 study, published at… Read More »A phase 1/2 multi-centre study provides results for the treatment of XLRP, promising a Phase 2/3 study to progress in 2025.
Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company based in Iselin, New Jersey, USA, has announced that the UK NICE (National Institute for Health and… Read More »Outlook Therapeutics (NASDAQ: OTLK) announce first and only approved ophthalmic formulation of bevacizumab (for treatment of wet AMD) in the EU and UK.
